PND56 BUDGET IMPACT ANALYSIS OF INCLUSION IN THE PUBLIC FINANCING OCRELIZUMAB THERAPY FOR PRIMARY-PROGREDIENT AND HIGHLY ACTIVE REMITTING FORMS OF MULTIPLE SCELEROSIS IN THE RUSSIAN FEDERATION

Nov 1, 2019, 00:00 AM
10.1016/j.jval.2019.09.1826
https://www.valueinhealthjournal.com/article/S1098-3015(19)34204-4/fulltext
Section Title :
Section Order : 11591
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(19)34204-4&doi=10.1016/j.jval.2019.09.1826
HEOR Topics :
Tags :
Regions :